The role of anthracyclines in epithelial ovarian cancer

This paper provides a survey on anthracycline treatment in ovarian cancer, focusing on toxicity and analysis of treatment results. Mete-analyses and s tudies in which anthracyclines have been combined with "standard" taxoid re gimens are reviewed. The data suggest that the addition of an anthracycline to front-line non-taxoid based therapy is beneficial. The addition of an a nthracycline to a combination of a taxoid and platinum derivative is ration ale and feasible and randomised trials are on their way to completion. It i s important that the final conclusions of these studies are based on long-t erm survival data, not just on the assessment of median differences in surv ival.